Technetium ⁹⁹ᵐTc oxidronic acid

Category C.

Animal reproduction studies have not been conducted with technetium ⁹⁹ᵐTc oxidronic acid. It is also not known whether technetium ⁹⁹ᵐTc oxidronic acid can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Technetium ⁹⁹ᵐTc oxidronic acid should be given to a pregnant woman only if clearly needed. Ideally, examinations using radiopharmaceuticals, especially those elective in nature, of a woman of childbearing capability should be performed during the first few (approximately 10) days following the onset of menses.

Technetium ⁹⁹ᵐTc oxidronic acid is excreted in human milk during lactation, therefore formula feedings should be substituted for breast feedings.

No long-term animal studies have been performed to evaluate carcinogenic or mutagenic potential or whether technetium ⁹⁹ᵐTc oxidronic acid affects fertility in males and females.

Hypersensitivity reactions, including life-threatening reactions, as well as nausea, vomiting and injection site reactions, have been infrequently reported with technetium ⁹⁹ᵐTc oxidronic acid use.